# Richardson Electronics, LTD.: Form 10-Q for the period ended Feb 27, 2021

- Company: [Richardson Electronics, LTD.](/companies/rell.md) (CIK 355948)
- Form: 10-Q
- Filed: 2021-04-08
- Accepted by EDGAR: Apr 8, 2021, 15:00 ET
- Period: 2021-02-27
- Accession: 0001564590-21-018143
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/355948/000156459021018143/rell-10q_20210227.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/355948/000156459021018143/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-02-27.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-11-29 to 2021-02-27 | $45.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-05-31 to 2021-02-27 | $126.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-11-29 to 2021-02-27 | $29.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2020-05-31 to 2021-02-27 | $84.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2020-11-29 to 2021-02-27 | $15.8m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-05-31 to 2021-02-27 | $42.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2020-11-29 to 2021-02-27 | $15.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-05-31 to 2021-02-27 | $41.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-11-29 to 2021-02-27 | $315.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-05-31 to 2021-02-27 | $550.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-11-29 to 2021-02-27 | $62.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-05-31 to 2021-02-27 | $239.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-11-29 to 2021-02-27 | $228.0k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-05-31 to 2021-02-27 | −$230.0k | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2020-11-29 to 2021-02-27 | 13,280,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-05-31 to 2021-02-27 | 13,194,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2020-11-29 to 2021-02-27 | $2.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Operating cash flow | 9 months, 2020-05-31 to 2021-02-27 | $3.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-11-29 to 2021-02-27 | $555.0k | us-gaap:PaymentsToAcquireProductiveAssets |
| Capital expenditure | 9 months, 2020-05-31 to 2021-02-27 | $1.8m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 3 months, 2020-11-29 to 2021-02-27 | $780.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Dividends paid | 9 months, 2020-05-31 to 2021-02-27 | $2.3m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2021-02-27 | $38.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-02-27 | $131.0m | us-gaap:AssetsCurrent |
| Total assets | at 2021-02-27 | $154.0m | us-gaap:Assets |
| Current liabilities | at 2021-02-27 | $31.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-02-27 | $34.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-02-27 | $119.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 30,217 characters.

*Certain statements in this report may constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. The terms “may,” “should,” “could,” “anticipate,” “believe,” “continues,” “estimate,” “expect,” “intend,” “objective,” “plan,” “potential,” “project” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. These statements are based on management’s current expectations, intentions or beliefs and are subject to a number of factors, assumptions and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause or contribute to such differences or that might otherwise impact the business include the risk factors set forth in Item 1A of this quarterly report on Form 10Q for the quarter ended February 27, 2021, as well as our Annual Report on Form 10-K filed on August 3, 2020. We undertake no obligation to update any such factor or to publicly announce the results of any revisions to any forward-looking statements contained herein whether as a result of new information, future events or otherwise.*

*In addition, while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not our responsibility.*

### INTRODUCTION

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to assist the reader in better understanding our business, results of operations, financial condition, changes in financial condition, critical accounting policies and estimates and significant developments. MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes appearing elsewhere in this filing. This section is organized as follows:

- **Business Overview**
- **Results of Operations –** an analysis and comparison of our consolidated results of operations for the three and nine month periods ended February 27, 2021 and February 29, 2020, as reflected in our consolidated statements of comprehensive income (loss).
- **Liquidity, Financial Position and Capital Resources –** a discussion of our primary sources and uses of cash for the nine month periods ended February 27, 2021 and February 29, 2020, and a discussion of changes in our financial position.

### Business Overview

Richardson Electronics, Ltd. is a leading global provider of engineered solutions, power grid and microwave tubes and related consumables; power conversion and RF and microwave components; high value flat panel detector solutions, replacement parts, tubes and service training for diagnostic imaging equipment; and customized display solutions. We serve customers in the alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific and semiconductor markets. The Company’s strategy is to provide specialized technical expertise and “engineered solutions” based on our core engineering and manufacturing capabilities. The Company provides solutions and adds value through design-in support, systems integration, prototype design and manufacturing, testing, logistics and aftermarket technical service and repair through its global infrastructure.

Our products include electron tubes and related components, microwave generators, subsystems used in semiconductor manufacturing and visual technology solutions. These products are used to control, switch or amplify electrical power signals, or are used as display devices in a variety of industrial, commercial, medical and communication applications.

We have three operating and reportable segments, which we define as follows:

Power and Microwave Technologies Group (“PMT”) combines our core engineered solutions capabilities, power grid and microwave tube business with new disruptive RF, Wireless and Power technologies. As a designer, manufacturer, technology partner and authorized distributor, PMT’s strategy is to provide specialized technical expertise and engineered solutions based on our core engineering and manufacturing capabilities on a global basis. We provide solutions and add value through design-in support, systems integration, prototype design and manufacturing, testing, logistics and aftermarket technical service and repair—all through our existing global infrastructure. PMT’s focus is on products for power, RF and microwave applications for customers in 5G, alternative energy, aviation, broadcast, communications, industrial, marine, medical, military, scientific and semiconductor markets. PMT focuses on various applications including broadcast transmission, CO2 laser cutting, diagnostic imaging, dielectric and induction heating, high energy transfer, high voltage switching, plasma, power conversion, radar and radiation oncology. PMT also offers its customers technical services for both microwave and industrial equipment.

Canvys provides customized display solutions serving the corporate enterprise, financial, healthcare, industrial and medical original equipment manufacturers markets. Our engineers design, manufacture, source and support a full spectrum of solutions to match the needs of our customers. We offer long term availability and proven custom display solutions that include touch screens, protective panels, custom enclosures, All-In-One computers, specialized cabinet finishes, application specific software packages and certification services. Our volume commitments are lower than the large display manufacturers, making us the ideal choice for companies with very specific design requirements. We partner with both private label manufacturing companies and leading branded hardware vendors to offer the highest quality display and touch solutions and customized computing platforms.

Healthcare manufactures, repairs, refurbishes and distributes high value replacement parts and equipment for the healthcare market including hospitals, medical centers, asset management companies, independent service organizations and multi-vendor service providers. Products include diagnostic imaging replacement parts for CT and MRI systems; replacement CT and MRI tubes; CT service training; MRI coils, cold heads and RF amplifiers; hydrogen thyratrons, klystrons, magnetrons; flat panel detector upgrades; pre-owned CT systems; and additional replacement solutions currently under development for the diagnostic imaging service market. Through a combination of newly developed products and partnerships, service offerings and training programs, we help our customers improve efficiency and deliver better clinical outcomes while lowering the cost of healthcare delivery.

We currently have operations in the following major geographic regions: North America, Asia/Pacific, Europe and Latin America.

### RESULTS OF OPERATIONS

### Financial Summary – Three Months Ended February 27, 2021

- The third quarter of fiscal 2021 and fiscal 2020 each contained 13 weeks.
- Net sales during the third quarter of fiscal 2021 were $45.2 million, an increase of 18.3%, compared to net sales of $38.2 million during the third quarter of fiscal 2020.
- Gross margin increased to 34.9% during the third quarter of fiscal 2021 compared to 33.1% during the third quarter of fiscal 2020.
- Selling, general and administrative expenses were $15.5 million, including the $1.6 million settlement, or 34.2% of net sales, during the third quarter of fiscal 2021 compared to $12.7 million, or 33.1% of net sales, during the third quarter of fiscal 2020.
- Operating income during the third quarter of fiscal 2021 was $0.3 million compared to operating income of $11,000 during the third quarter of fiscal 2020.
- Net income during the third quarter of fiscal 2021 was $0.2 million compared to net loss of $0.1 million during the third quarter of fiscal 2020.

### Financial Summary – Nine Months Ended February 27, 2021

- The first nine months of fiscal 2021 and fiscal 2020 each contained 39 weeks.
- Net sales during the first nine months of fiscal 2021 were $126.5 million, an increase of 6.7%, compared to net sales of $118.5 million during the first nine months of fiscal 2020.
- Gross margin increased to 33.6% during the first nine months of fiscal 2021 compared to 32.3% during the first nine months of fiscal 2020.
- Selling, general and administrative expenses were $41.9 million, including the $1.6 million settlement, or 33.2% of net sales, during the first nine months of fiscal 2021 compared to $38.7 million, or 32.6% of net sales, during the first nine months of fiscal 2020.
- Operating income during the first nine months of fiscal 2021 was $0.6 million compared to operating loss of $0.4 million during the first nine months of fiscal 2020.
- Net loss during the first nine months of fiscal 2021 was $0.2 million compared to net loss of $0.6 million during the first nine months of fiscal 2020.

### Net Sales and Gross Profit Analysis

Net sales by segment and percent change during the third quarter and first nine months of fiscal 2021 and fiscal 2020 were as follows (*in thousands):*

| Net Sales | Three Months Ended February 27, 2021 | February 29, 2020 | FY21 vs. FY20 % Change |
| --- | ---: | ---: | ---: |
| PMT | $35,237 | $28,988 | 21.6% |
| Canvys | 7,078 | 7,200 | -1.7% |
| Healthcare | 2,920 | 2,061 | 41.7% |
| Total | $45,235 | $38,249 | 18.3% |

|  | Nine Months Ended February 27, 2021 | February 29, 2020 | FY21 vs. FY20 % Change |
| --- | ---: | ---: | ---: |
| PMT | $98,418 | $89,158 | 10.4% |
| Canvys | 20,491 | 22,333 | -8.2% |
| Healthcare | 7,556 | 7,045 | 7.3% |
| Total | $126,465 | $118,536 | 6.7% |

During the third quarter of fiscal 2021, consolidated net sales increased 18.3% compared to the third quarter of fiscal 2020. Sales for PMT increased 21.6%, sales for Canvys decreased 1.7% and sales for Healthcare increased 41.7%. The increase in PMT was mainly due to strong growth from our Power and Microwave new technology partners in various applications including Power Management and 5G infrastructure and increased revenue from our Semiconductor Wafer Fabrication customers buying engineered solutions. We also had growth in various Electron Device product lines. The decrease in Canvys was primarily due to continuing struggles in the European market related to the COVID-19 impact on demand for equipment partially offset by strong sales in the North American market. The increase in Healthcare was primarily due to a significant increase in demand for the ALTA 750DTM tubes coupled with increased equipment sales in Latin America.

During the first nine months of fiscal 2021, consolidated net sales increased 6.7% compared to the first nine months of fiscal 2020. Sales for PMT increased 10.4%, sales for Canvys decreased 8.2% and sales for Healthcare increased 7.3%. The increase in PMT was mainly due to strong growth in bookings and billings from our Power Management and RF and microwave components with continued growth in the Semiconductor Wafer Fab market. We also had growth in various Electron Device product lines. The decrease in Canvys was primarily due to continuing struggles in the European market related to the COVID-19 impact on demand for equipment partially offset by strong sales in the North American market. The increase in Healthcare was due to an increase in demand for the ALTA 750DTM tubes.

Gross profit by segment and percent of net sales for the third quarter and first nine months of fiscal 2021 and fiscal 2020 were as follows (*in thousands):*

| Gross Profit | Three Months Ended February 27, 2021 | % of Net Sales | February 29, 2020 | % of Net Sales |
| --- | ---: | ---: | ---: | ---: |
| PMT | $12,308 | 34.9% | $9,519 | 32.8% |
| Canvys | 2,493 | 35.2% | 2,362 | 32.8% |
| Healthcare | 965 | 33.0% | 789 | 38.3% |
| Total | $15,766 | 34.9% | $12,670 | 33.1% |

|  | Nine Months Ended February 27, 2021 | % of Net Sales | February 29, 2020 | % of Net Sales |
| --- | ---: | ---: | ---: | ---: |
| PMT | $33,530 | 34.1% | $28,547 | 32.0% |
| Canvys | 7,156 | 34.9% | 7,268 | 32.5% |
| Healthcare | 1,782 | 23.6% | 2,486 | 35.3% |
| Total | $42,468 | 33.6% | $38,301 | 32.3% |

Gross profit reflects the distribution and manufacturing product margin less manufacturing variances, inventory obsolescence charges, customer returns, scrap and cycle count adjustments, engineering costs and other provisions.

Consolidated gross profit increased to $15.8 million during the third quarter of fiscal 2021 compared to $12.7 million during the third quarter of fiscal 2020. Consolidated gross margin as a percentage of net sales increased to 34.9% during the third quarter of fiscal 2021 from 33.1% during the third quarter of fiscal 2020, primarily due to favorable product mix in both PMT and Canvys, partially offset by product mix in Healthcare.

Consolidated gross profit increased to $42.5 million during the first nine months of fiscal 2021 compared to $38.3 million during the first nine months of fiscal 2020. Consolidated gross margin as a percentage of net sales increased to 33.6% during the first nine months of fiscal 2021 from 32.3% during the first nine months of fiscal 2020, primarily due to improved manufacturing efficiencies in PMT and favorable product mix in both PMT and Canvys. These increases were partially offset by under absorbed manufacturing expenses in Healthcare during the first half of fiscal 2021.

### Power and Microwave Technologies Group

PMT net sales increased 21.6% to $35.2 million during the third quarter of fiscal 2021 from $29.0 million during the third quarter of fiscal 2020. The increase was mainly due to strong growth from our Power and Microwave new technology partners in various applications including Power Management and 5G infrastructure and increased revenue from our Semiconductor Wafer Fabrication customers buying engineered solutions. We also had growth in various Electron Device product lines. Gross margin as a percentage of net sales increased to 34.9% during the third quarter of fiscal 2021 as compared to 32.8% during the third quarter of fiscal 2020 primarily due to favorable product mix.

PMT net sales increased 10.4% to $98.4 million during the first nine months of fiscal 2021 from $89.2 million during the first nine months of fiscal 2020. The increase was mainly due to strong growth in bookings and billings from our Power Management and RF and microwave components with continued growth in the Semiconductor Wafer Fab market. We also had growth in various Electron Device product lines. Gross margin as a percentage of net sales increased to 34.1% during the first nine months of fiscal 2021 as compared to 32.0% during the first nine months of fiscal 2020 due to favorable product mix and improved manufacturing efficiencies.

### Canvys

Canvys net sales decreased 1.7% to $7.1 million during the third quarter of fiscal 2021 from $7.2 million during the third quarter of fiscal 2020 primarily due to continuing struggles in the European market related to the COVID-19 impact on demand for equipment partially offset by strong sales in the North American market. Gross margin as a percentage of net sales increased to 35.2% during the third quarter of fiscal 2021 from 32.8% during the third quarter of fiscal 2020 due to favorable product mix.

Canvys net sales decreased 8.2% to $20.5 million during the first nine months of fiscal 2021 from $22.3 million during the first nine months of fiscal 2020 primarily due to continuing struggles in the European market related to the COVID-19 impact on demand for equipment partially offset by strong sales in the North American market. Gross margin as a percentage of net sales increased to 34.9% during the first nine months of fiscal 2021 as compared to 32.5% during the first nine months of fiscal 2020 due to favorable product mix and foreign currency change impact.

### Healthcare

Healthcare net sales increased 41.7% to $2.9 million during the third quarter of fiscal 2021 from $2.1 million during the third quarter of fiscal 2020. The increase in sales was primarily due to a significant increase in demand for the ALTA 750DTM tubes coupled with increased equipment sales in Latin America. Gross margin as a percentage of net sales decreased to 33.0% during the third quarter of fiscal 2021 as compared to 38.3% during the third quarter of fiscal 2020 primarily due to product mix.

Healthcare net sales increased 7.3% to $7.6 million during the first nine months of fiscal 2021 from $7.0 million during the first nine months of fiscal 2020 due to an increase in demand for the ALTA 750DTM tubes. Gross margin as a percentage of net sales decreased to 23.6% during the first nine months of fiscal 2021 as compared to 35.3% during the first nine months of fiscal 2020 due to under absorbed manufacturing expenses in the first half of fiscal 2021.

### Legal Settlement

On October 15, 2018, Varex Imaging Corporation (“Varex”) filed its original Complaint (Case No. 1:18-cv-06911) against Richardson Electronics Ltd. (“Richardson”) in the Northern District of Illinois, which was subsequently amended on November 27, 2018. Varex alleged counts of infringement of U.S. Patent Nos. 6,456,692 and 6,519,317. Subsequently, on October 24, 2018, Varex filed a motion for preliminary injunction to stop the sale of Richardson’s ALTA750 TM product. Richardson filed an opposition to the preliminary injunction. In January 2019, the Court took evidence on the preliminary injunction issue. On September 30, 2019, the Court denied Varex’s Motion for Preliminary Injunction. On August 6, 2020, Varex amended its Complaint to add claims of trade secret misappropriation and Richardson moved to dismiss that Amended Complaint on September 9, 2020. On April 2, 2021, as part of an overall settlement where Richardson did not admit liability but wanted to move forward, Richardson agreed to pay Varex $1.6 million to settle this matter, which is recorded in selling, general and administrative expenses within the Consolidated Statements of Comprehensive Income (Loss).

### Selling, General and Administrative Expenses

Selling, general and administrative expenses increased to $15.5 million during the third quarter of fiscal 2021 from $12.7 million in the third quarter of fiscal 2020. This increase included the $1.6 million legal settlement. The increase also resulted from higher employee compensation expense and legal fees, partially offset by lower travel expenses.

Selling, general and administrative expenses increased to $41.9 million during the first nine months of fiscal 2021 from $38.7 million in the first nine months of fiscal 2020. This increase included the $1.6 million legal settlement. The remainder of the increase was primarily due to higher employee compensation expense and legal fees, partially offset by lower travel and consulting expenses.

### Other Income/Expense

Other income/expense was expense of less than $0.1 million during the third quarter of fiscal 2021, compared to income of $0.1 million during the third quarter of fiscal 2020. Other income/expense during the third quarter of fiscal 2020 included $0.1 million of investment/interest income. Our foreign exchange gains and losses are primarily due to the translation of U.S. dollars held in non-U.S. entities. We currently do not utilize derivative instruments to manage our exposure to foreign currency.

Other income/expense was expense of $0.5 million during the first nine months of fiscal 2021, compared to income of $0.2 million during the first nine months of fiscal 2020. Other income/expense during the first nine months of fiscal 2021 included $0.6 million of foreign exchange losses partially offset by less than $0.1 million of investment/interest income. Other income/expense during the first nine months of fiscal 2020 included $0.3 million of investment/interest income partially offset by $0.1 million of foreign exchange losses.

### Income Tax Provision

The income tax provision was $0.1 million for the third quarter of fiscal 2021 as compared to $0.2 million for the third quarter of fiscal 2020. The income tax provision reflected a provision for foreign income taxes, which was lower than in the prior year’s third quarter, and the offset of a U.S. tax provision against the valuation allowance.

We recorded an income tax provision of $0.2 million and $0.4 million for the first nine months of fiscal 2021 and the first nine months of fiscal 2020, respectively. The income tax provision reflected a provision for foreign income taxes, which was lower than in the prior year’s first nine months, and no U.S. tax benefit due to the valuation allowance recorded against the net operating loss.

In the normal course of business, we are subject to examination by taxing authorities throughout the world. Generally, years prior to fiscal 2015 are closed for examination under the statute of limitation for U.S. federal, U.S. state and local or non-U.S. tax jurisdictions. We are currently under examination in Thailand (fiscal 2008 through 2011). Our primary foreign tax jurisdictions are Germany and the Netherlands. We have tax years open in Germany beginning in fiscal 2015 and the Netherlands beginning in fiscal 2018.

### Net Income (Loss) and Per Share Data

Net income during the third quarter of fiscal 2021 was $0.2 million, or $0.02 per diluted common share and $0.02 per Class B diluted common share as compared to net loss of $0.1 million during the third quarter of fiscal 2020 or ($0.01) per diluted common share and ($0.01) per Class B diluted common share.

Net loss during the first nine months of fiscal 2021 was $0.2 million or ($0.02) per diluted common share and ($0.02) per Class B diluted common share as compared to net loss of $0.6 million during the first nine months of fiscal 2020 or ($0.04) per diluted common share and ($0.04) per Class B diluted common share.

### LIQUIDITY, FINANCIAL POSITION AND CAPITAL RESOURCES

Our operations and cash needs have been primarily financed through cash on hand and investments.

Cash and cash equivalents were $38.4 million at February 27, 2021. Investments included a CD classified as short-term investment of $9.0 million. Total cash and investments were $47.4 million at February 27, 2021. Cash, cash equivalents and investments at February 27, 2021 consisted of $30.5 million in North America, $8.3 million in Europe, $1.0 million in Latin America and $7.6 million in Asia/Pacific. We repatriated a total of $0.7 million to the United States in the third quarter of fiscal 2021, which included $0.5 million from our entity in Korea and $0.2 million from our entity in Italy. Although the Tax Cuts and Jobs Act generally eliminated federal income tax on future cash repatriation to the United States, cash repatriation may be subject to state and local taxes, withholding or similar taxes. See Note 9 “Income Taxes” of the notes to our consolidated financial statements in Part II, Item 8 of our Annual Report on Form 10-K for the year ended May 30, 2020, filed August 3, 2020 for further information.

Cash, cash equivalents and investments were $46.5 million at May 30, 2020. Cash, cash equivalents and investments at May 30, 2020, consisted of $30.6 million in North America, $8.3 million in Europe, $0.9 million in Latin America and $6.7 million in Asia/Pacific. We repatriated a total of $8.5 million to the United States in fiscal 2020 from several of our foreign entities. This amount includes $4.4 million from our entities in Germany and the Netherlands in the second quarter of fiscal 2020, $1.5 million from our entity in Japan in the third quarter of fiscal 2020 and $1.0 million from our entity in Italy in the fourth quarter of fiscal 2020.

The Company continues to monitor the impact of the COVID-19 outbreak on its supply chain, manufacturing and distribution operations, customers and employees, as well as the U.S. economy in general. However, due to the uncertainty as to when governmental restrictions on business will be fully lifted, the impact thereof, and the duration and widespread nature of the COVID-19 outbreak, the Company cannot currently predict the long-term impact on its operations and financial results. The uncertainties associated with the COVID-19 outbreak include potential adverse effects on the overall economy, the Company’s supply chain, transportation services, employees and customers. The COVID-19 outbreak could adversely affect the Company’s revenues, earnings, liquidity and cash flows and may require significant actions in response, including expense reductions. Conditions surrounding COVID-19 change rapidly and additional impacts of which the Company is not currently aware may arise. Based on past performance and current expectations, we believe that the existing sources of liquidity, including current cash and investments, will provide sufficient resources to meet known capital requirements and working capital needs through the next twelve months.

### Cash Flows from Operating Activities

The cash provided by (used in) operating activities primarily resulted from net income (loss) adjusted for non-cash items and changes in our operating assets and liabilities.

Operating activities provided $3.9 million of cash during the first nine months of fiscal 2021. We had a net loss of $0.2 million during the first nine months of fiscal 2021, which included non-cash stock-based compensation expense of $0.5 million associated with the issuance of stock option and restricted stock awards, $0.7 million for inventory reserve provisions and depreciation and amortization expense of $2.6 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities resulted in cash provided of $0.3 million during the first nine months of fiscal 2021, net of foreign currency exchange gains and losses, included an increase in accrued liabilities of $4.3 million, partially offset by a decrease of $2.0 million in accounts payable, an increase in accounts receivable of $1.0 million and an increase in inventory of $0.9 million. The increase in accrued liabilities was mainly due to a legal settlement and timing of employee compensation and payroll tax payments as well as the timing of other payments. The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services. The increase in accounts receivable was primarily due to the sales increase in fiscal 2021. The majority of the inventory increase was to support the electron tube and RF and microwave components business.

Operating activities used $2.4 million of cash during the first nine months of fiscal 2020. We had a net loss of $0.6 million during the first nine months of fiscal 2020, which included non-cash stock-based compensation expense of $0.5 million associated with the issuance of stock option and restricted stock awards, $0.5 million for inventory reserve provisions and depreciation and amortization expense of $2.5 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities resulted in a use of cash of $5.4 million during the first nine months of fiscal 2020, net of foreign currency exchange gains and losses, included an increase in inventory of $4.2 million, a decrease of $2.1 million in accounts payable and a decrease in accrued liabilities of $0.2 million partially offset by a decrease in accounts receivable of $1.1 million. The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services. The majority of the inventory increase was to support the continued growth of our electron tube and RF and Power Technologies groups.

### Cash Flows from Investing Activities

The cash flow provided by (used in) investing activities consisted primarily of purchases of investments and capital expenditures partially offset by proceeds from the maturities of investments.

Cash provided by investing activities of $5.2 million during the first nine months of fiscal 2021 included proceeds from the maturities of investments of $16.0 million, partially offset by purchases of investments of $9.0 million and $1.8 million in capital expenditures. Capital expenditures related primarily to capital used for our Healthcare business and our IT system.

Cash used in investing activities of $6.2 million during the first nine months of fiscal 2020 included purchases of investments of $13.0 million and $1.2 million in capital expenditures, partially offset by proceeds from the maturities of investments of $8.0 million. Capital expenditures related primarily to capital used for our IT system, Healthcare and LaFox manufacturing businesses.

Our purchases of investments consisted of CDs. Purchasing of future investments may vary from period to period due to interest and foreign currency exchange rates.

### Cash Flows from Financing Activities

The cash flow used in financing activities consisted primarily of cash dividends paid.

Cash used in financing activities of $2.5 million during the first nine months of fiscal 2021 primarily resulted from cash used to pay dividends.

Cash used in financing activities of $2.4 million during the first nine months of fiscal 2020 primarily resulted from cash used to pay dividends.

All future payments of dividends are at the discretion of the Board of Directors. Dividend payments will depend on earnings, capital requirements, operating conditions and such other factors that the Board may deem relevant.

## Market risk

As filed, 846 characters.

### Risk Management and Market Sensitive Financial Instruments

We are exposed to many different market risks with the various industries we serve. The primary financial risk we are exposed to is foreign currency exchange, as certain operations, assets and liabilities of ours are denominated in foreign currencies. We manage these risks through normal operating and financing activities.

The interpretation and analysis of these disclosures should not be considered in isolation since such variances in exchange rates would likely influence other economic factors. Such factors, which are not readily quantifiable, would likely also affect our operations. Additional disclosure regarding various market risks are set forth in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended May 30, 2020, filed August 3, 2020.

## Controls and procedures

As filed, 1,611 characters.

(a) Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of February 27, 2021.

Disclosure controls and procedures are intended to provide reasonable assurance that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to management, including the Company’s Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.

(b) Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the third quarter of fiscal 2021 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 165 characters.

There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended May 30, 2020, filed August 3, 2020.

Filed Apr 8, 2021.
Source: SEC EDGAR, the filing index for accession 0001564590-21-018143. Last ingested by Listed: Nov 10, 2026, 23:29 ET. No prices; not investment advice.
